荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元同比扭亏为盈

智通财经02-27

智通财经APP讯，荣昌生物(09995)发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%;归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈;基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加;此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2614837190?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-27 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614837190","market":"hk","top_or_hot":-1,"title":"荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈","media":"智通财经","content":"<div>\n<p>智通财经APP讯，荣昌生物(09995)发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%;归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈;基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加;此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408351.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 19:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1408351.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，荣昌生物(09995)发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%;归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈;基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加;此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408351.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1408351.html","article_id":"2614837190","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614837190","pubTimestamp":1772191467,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，荣昌生物(09995)发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%;归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈;基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加;此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术授权收入大幅增加。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","BK1583":"高瓴概念","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1574":"生物医药B类股","09995":"荣昌生物","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造"},"translate_title":"Rongchang Biotech (09995) released its annual results, with a profit attributable to shareholders of 709 million yuan turning losses into profits year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1.5,"09995":1.5},"content_text":"智通财经APP讯，荣昌生物(09995)发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%;归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈;基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加;此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术授权收入大幅增加。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614837190","isCrawlerRequest":true}

荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈

精彩评论

荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元同比扭亏为盈